Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene in Mild to Moderate Alzheimer's Disease
NCT01782742Phase 2Completed
- Sponsor
- Cleveland Clinic
- Start
- Feb 2013
- Primary completion
- Aug 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Bexarotene with Placebo (2 arms). Primary endpoint: Composite Amyloid Burden of the Brain at 4 weeks. Started Feb 2013; status: completed.
02
Drugs
bexarotene
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01782742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01782742.